Targeted mutation detection in breast cancer using MammaSeqTM
N. G. Smith, R. Gyanchandani, G. T. Gurda, P. C. Lucas, R. Hartmaier, A. M. Brufsky, S. Puhalla, A. Bahreini, K. Kota, A. Wald, Y. E. Nikiforov, M. N. Nikiforova, S. Oesterrich, A. V. Lee
The paper develops MammaSeq, a targeted NGS panel for detecting clinically actionable mutations in breast cancer, showing it identifies actionable variants in 48% of solid tumors and 29% of cfDNA samples.
bioRxiv · Feb 13, 2018Cancer Biology